Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268884 | 0.88 | HPGD (0.52) | HPGDMAPK1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL5266012 | 0.83 | NPSR1 (0.69) | MAPK1MAPTALDH1A1NPSR1NPC1 | |
| SCHEMBL5391948 | 0.83 | CYP1A2 (0.76) | MAPK1CYP1A2CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL5391945 | 0.83 | CYP1A2 (0.63) | HPGDMAPK1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL5107776 | 0.81 | MAPK1 (0.55) | HPGDMAPK1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL5107772 | 0.81 | MAPT (0.54) | HPGDMAPK1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL9431194 | 0.80 | MAPT (0.67) | MAPK1MAPTALDH1A1NPSR1NPC1 | |
| SCHEMBL7867868 | 0.79 | MAPT (0.66) | MAPTALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL7864977 | 0.79 | MAPT (0.66) | MAPTALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL7857190 | 0.79 | MAPT (0.66) | MAPTALDH1A1NPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20040162311-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040010004-A1 | Benzimidazole derivatives | TEIJIN LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1249450-A1 | BENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162311-A1 | Benzimidazole derivative | CMA1, CBR3, CBR1 | HRH4 4/4885HPGD 2370/4885MAPK1 1202/4885 |
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | HRH4 260/4885HPGD 1220/4885MAPK1 1817/4885 |
| US-20040010004-A1 | Benzimidazole derivatives | CMA1, CBR3, CBR1 | HRH4 4/4885HPGD 2482/4885MAPK1 1049/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | HRH4 352/4885HPGD 1568/4885MAPK1 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.